Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

Benzinga Newsdesk www.benzinga.com Positive 68.8%

Neg 0% Neu 0% Pos 68.8%

Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.